Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience.
作者： Ermelinda De Maio , Adriano Gravina , Carmen Pacilio , Gerardo Amabile , Vincenzo Labonia
关键词:
摘要: Background Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard treatment.
biomedcentral.com
springer.com
core.ac.uk
elsevier.com
paperity.org参考文章(25)
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. Journal of the National Cancer Institute. ,vol. 93, pp. 979- 989 ,(2001) , 10.1093/JNCI/93.13.979
Aron Goldhirsch, John H. Glick, Richard D. Gelber, Alan S. Coates, Hans-Jörg Senn, Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. Journal of Clinical Oncology. ,vol. 19, pp. 3817- 3827 ,(2001) , 10.1200/JCO.2001.19.18.3817
Martine Extermann, Lodovico Balducci, Gary H. Lyman, What Threshold for Adjuvant Therapy in Older Breast Cancer Patients Journal of Clinical Oncology. ,vol. 18, pp. 1709- 1717 ,(2000) , 10.1200/JCO.2000.18.8.1709
John D. Hainsworth, Howard A. Burris, Denise A. Yardley, James E. Bradof, Manuel Grimaldi, Leonard A. Kalman, Tim Sullivan, Margaret Baker, Joan B. Erland, F. Anthony Greco, Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial Journal of Clinical Oncology. ,vol. 19, pp. 3500- 3505 ,(2001) , 10.1200/JCO.2001.19.15.3500
M N Levine, V H Bramwell, K I Pritchard, B D Norris, L E Shepherd, H Abu-Zahra, B Findlay, D Warr, D Bowman, J Myles, A Arnold, T Vandenberg, R MacKenzie, J Robert, J Ottaway, M Burnell, C K Williams, D Tu, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 16, pp. 2651- 2658 ,(1998) , 10.1200/JCO.1998.16.8.2651
Jeanne S. Mandelblatt, Jack Hadley, Jon F. Kerner, Kevin A. Schulman, Karen Gold, Jackie Dunmore-Griffith, Stephen Edge, Edward Guadagnoli, John J. Lynch, Neal J. Meropol, Jane C. Weeks, Rodger Winn, , Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physician influences Cancer. ,vol. 89, pp. 561- 573 ,(2000) , 10.1002/1097-0142(20000801)89:3<561::AID-CNCR11>3.0.CO;2-A
Aron Goldhirsch, William C. Wood, Richard D. Gelber, Alan S. Coates, Beat Thürlimann, Hans-Jörg Senn, Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer Journal of Clinical Oncology. ,vol. 21, pp. 3357- 3365 ,(2003) , 10.1200/JCO.2003.04.576
Angela DeMichele, Mary Putt, Yawei Zhang, John H. Glick, Sandra Norman, Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer. ,vol. 97, pp. 2150- 2159 ,(2003) , 10.1002/CNCR.11338
Stacy Woodard, Padma C. Nadella, Linda Kotur, John Wilson, William E. Burak, Charles L. Shapiro, Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer. ,vol. 98, pp. 1141- 1149 ,(2003) , 10.1002/CNCR.11640
L. Wyld, M. W. R. Reed, The need for targeted research into breast cancer in the elderly British Journal of Surgery. ,vol. 90, pp. 388- 399 ,(2003) , 10.1002/BJS.4124